Comparing the current results to its competitors, Puma Biotechnology Inc reported Revenue decrease in the 1 quarter 2026 year on year by -2.59 %, despite the revenue increase by the most of its competitors of 20.15 %, recorded in the same quarter.
Puma Biotechnology Inc , slower than the average decrease reported by the company's competitors of -35.49 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -35.49 %
Puma Biotechnology Inc 's Comment on Competition and Industry Peers
The company operates in a competitive cancer treatment market alongside major pharmaceutical, biotechnology, and specialty cancer firms. Competitors include Genentech, Novartis, Roche, Boehringer Ingelheim, Lilly, Merck, AbbVie, Pfizer, Amgen, Daiichi Sankyo, Jazz, and Seagen. Merck, AbbVie, Amgen, Daiichi Sankyo, and Jazz are developing drugs for small cell lung cancer, while the others focus on early-stage and metastatic HER2-positive breast cancer or related cancer types. The company notes that many competitors possess greater financial resources and expertise in drug development and commercialization. Industry mergers and acquisitions may further consolidate resources among fewer competitors. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies.
February 27, 2025
for CSIMarket.com : Comparative Financial Performance and Market Positioning of Puma Biotechnology Inc. In an era where biopharmaceutical companies are pivotal in developing innovative therapies, Puma Biotechnology Inc. (NASDAQ: PBYI) has demonstrated ...
Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.
Sources:
Puma Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Puma Biotechnology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
